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INTRODUCTION
Invasive cancer of cervix is considered as a preventable disease because it has a long preinvasive state, 
cervical cytology screening programs are currently available and the treatment of preinvasive lesions is 
effective. Normally the lifetime probability for developing cervical cancer is 1:128.Although screening 
programs in US are well established, it is estimated that 30% of cervical cancer cases will occur in 
women who have never had a PAP test. In developing countries, this percentage approaches sixty.(1)
Human Papilloma Virus is the major aetiological agent for cervical cancer, the second common cancer 
among the women everywhere in the world (Munoz et al 1994). This virus is also implicated in other 
anogenital cancers.HPV is among the most important viruses in causation of cancer. A large number of 
epidemiological, biological and chemical studies are underway to get to know the nature of this 
infection and its outcome. The prospects of HPV vaccine in preventing cervical cancer make it the 
most suitable target for studies in low resource settings with high morbidity and mortality from cervical 
cancer.
Cervical cancer is the second most common cancer among women worldwide. The majority of the 
cases occur in the developing world, where in most countries, it is the leading cause of cancer mortality 
in women. (2)
An estimated 470,000 new cases of cancer cervix are diagnosed each year worldwide and 80% of these 
occur in the developing world. A quarter of the global burden is experienced in India, where about 
126,000 new cases and 71000 deaths attributable to cervical cancer are estimated to occur each 
year(3,4). Cancer cervix constitutes15-51% of all female cancers and rates of age-standardised 
incidence range from 17.5 to 55% per 100,000 women in different regions of India(4,5). More than 
80% are diagnosed at an advanced clinical stage and 5 year survival is less than 40%(6,7). In many 
developed countries a decline in the incidence  and mortality caused by cervical cancer  has been 
observed in the past 30 years as a result of screening by cytology(8,9). 
India has the burden of having the largest number of women with cervical cancer contributing to18% of 
world’s total number. One out of every 5 women in world suffering from cervical cancer is from India 
(10).
Tamilnadu has the large incidence of cervical cancer with very high number of 28.6 per 100,000 
women from Tiruvallur district (ICMR) (11). Chennai PBCR has had the highest incidence rate of 
cervical cancer among the Indian PBCRs. This AAR is somewhat lower than that seen in the registries 
in Africa and Brazil (Parkin et al 2002). The district wise MAARS indicate a belt of high incidence 
rates even higher than that in Chennai PBCR in North-eastern districts of Tamilnadu including 
Pondicherry which had the highest MAAR of 39.2/100,000, closely followed by Villupuram with a 
MAAR of 31.1/100,000, and Cuddalore with MAAR 29.9/100,000 (cancer atlas india.org).
Worldwide HPV 16 and 18 cause approximately 70% of cervical cancer, AIS,CIN 3,VIN2 and VaIN 
2/3and 50% CIN 2-the eight most common high risk genotypes(HPV16,18,45,31,33,52,58 &35) 
account for 90% of cervical cancer cases. Apart from HPV 16/18, each individual genotype causes a 
small proportion(less than 5%)of cases(12-16).
HPV 6,11,16 & 18 cause 35-50 % of all CIN1,VIN1 &Va1N1cases(17).It is now universally accepted 
that nearly all cervical cancers of high grade intraepithelial neoplasia are associated with high risk HPV 
types. Owing to the strong association, it has been suggested that high risk HPV detection might be 
used as a tool to identify women at risk for subsequent development of cervical cancer. Guidelines 
need to be formulated for HPV testing in cervical cancer screening and for vaccination. For this, age 
prevalence of high risk HPV in cytologically normal cervical smear needs to be determined.
With this aim, we undertook the present study to determine the prevalence of high risk HPV 
infections in women with symptoms of chronic discharge per vaginum attending our Gynaecology 
OPD and those with cancer cervix.
REVIEW OF LITERATURE
CERVICAL INTRAEPITHELIAL NEOPLASIA
The concept of pre invasive disease of cervix was introduced in 1947, when it was recognised that 
epithelial changes could be identified that had the appearance of invasive cancer but were confined to 
the epithelium (17.1).Subsequent studies showed that if these lesions are not treated, they can progress 
to cervical cancer (18).Improvement in cytological assessment led to the identification of early 
precursor lesions called dysplasia, which signalled possible development of future cancer. The concept 
of CIN was introduced in 1968 when Richard indicated that all dysplasias have the potential of 
progression (19).
It is now recognised that most CIN 1 & some CIN 2 lesions regress spontaneously if treated (20); 
Nevertheless CIN refers to a lesion that may progress to invasive carcinoma. This term is equivalent to 
the term dysplasia, which means abnormal maturation; consequently proliferating metaplasia without 
mitotic activity should not be called dysplasia. Squamous metaplasia should not be diagnosed as 
dysplasia or CIN because it does not progress to invasive cancer.
SQUAMOCOLUMNAR JUNCTION
The squamocolumnar junction rarely remains restricted to the external os. Instead it is a dynamic point 
that changes in response to puberty, pregnancy, menopause and hormonal stimulation. Lactobacilli act 
on the glycogen to lower the pH after menarche, stimulating the sub columnar reserve cells to undergo 
metaplasia.
Metaplasia advances from the original squamocolumnar inward, toward the external os and over the 
columnar villi. This process establishes an area called the transformation zone. The transformation 
zone extends from the original squamocolumnar junction to the physiologically active 
squamocolumnar junction.
In most cases, CIN is believed to originate as a single focus in the transformation zone at the advancing 
squamocolumnar junction. The anterior lip of the cervix is twice as likely to develop CIN as the 
posterior lip, and the CIN rarely originates in the lateral angles. The entire SCJ with early metaplastic 
cells is susceptible to oncogenic factors, which may cause these cells to transform into CIN. Therefore, 
CIN is most likely to begin either during menarche or after pregnancy when metaplasia is most active. 
Conversely, after menopause there is little metaplasia and is at a lower risk of developing CIN.
COLUMNAR EPITHELIUM
It has a single layer of columnar cells with mucus at the top and a round nucleus at the base. The 
glandular epithelium is composed of numerous ridges, clefts and infoldings, and when covered by 
squamous metaplasia, leads to the appearance of gland openings.
METAPLASTIC EPITHELIUM
Metaplastic epithelium found at the SCJ, begins in the subcolumnar reserve cells. Under stimulation of 
lower vaginal acidity, the reserve cells proliferate, lifting the columnar epithelium. The immature 
metaplastic cells have a large nuclei and a small amount of cytoplasm without glycogen. As the cells 
mature normally, they produce glycogen, eventually forming the 4 layers of epithelium. The 
metaplastic process begins at the tips of the columnar villi, which are exposed first to the acid vaginal 
environment. As the metaplasia replaces the columnar epithelium, the central capillary of the villus 
regresses and the epithelium flattens out, leaving the epithelium with its typically vascular network. As 
metaplasia proceeds into the cervical clefts, it replaces the columnar epithelium and similarly flattens 
the epithelium. The deeper clefts, however, may not be completely replaced by metaplastic epithelium, 
leaving mucus secreting columnar epithelium trapped under the squamous epithelium. Some of these 
glands open onto the surface; others are completely encased with mucus collecting in nabothian cysts. 
Gland openings and nabothian cysts mark the original SCJ and the outer edge of the original 
transformation zone.
NORMAL TRANSFORMATION ZONE
The original squamous epithelium of vagina and exocervix has 4 layers
1. The basal layer is a single row of immature cells with large nuclei and a small amount of 
cytoplasm.
2. The parabasal layers include 2-4 rows of immature cells that have normal mitotic figures and 
provide the replacement cells for the overlying epithelium.
3. The intermediate layers include 4-6 rows of cells with larger amounts of cytoplasm in a 
polyhedral shape separated by an intercellular space. Intercellular bridges, where differentiation 
of glycogen production occurs, can be identified with a light microscopy
4. Superficial layers include 5-8 rows of flattened cells with small uniform nuclei and a cytoplasm 
filled with glycogen. The nucleus becomes pyknotic, and the cells detach from the surface. 
These cells form the basis for Pap testing.
CIN
CIN is graded according to the proportion of epithelium occupied by undifferentiated cells. In CIN 
1 (Mild dysplasia) only the basal third or less of the epithelium is occupied by the undifferentiated 
cells. A lesion is classified as CIN 2 (Moderate dysplasia) if the cells occupy between 1/3 and 2/3rd 
of the epithelium. If more than 2/3rds of the epithelial thickness is occupied by undifferentiated 
cells, a diagnosis of CIN 3 is made .In most severe form of CIN 3 ,atypical cells occupy the full 
thickness of the epithelium and mitotic figures, often abnormal, are seen at all times(21).
It takes 1-17 years for an in situ lesion to become invasive, with an average of 10 years. So the 
mean age at which carcinoma in situ is found is 35 years, the comparable figures for micro invasive 
carcinoma and invasive cancer being 44 and 53 respectively. Recently in developed countries there 
is second peak of invasive carcinoma at between 30 and 40 years and in these younger women the 
change from an in situ to invasive carcinoma appears to be much faster(weeks or months rather 
than years).Coexisting HPV infection may accelerate the pace of the disease.
COLPOSCOPY OF THE CERVIX
It is the examination of the vagina and the cervix in vivo with a binocular microscope (the 
colposcope) using an external white light for illumination. Currently, screening methods for 
cervical cancer include cervical cytology (Pap smear), visual inspection after application of cetic 
acid (VIA), or Lugols iodine (VILI) and the high risk HPV DNA tests. Colposcopy is used to 
obtain directed cervical biopsies in screen positive women for the histopathologic diagnosis of 
cervical intraepithelial (preinvasive) or invasive cancer.
INDICATIONS FOR COLPOSCOPY
1. Evaluation of the women with squamous or glandular cell abnormalities on Pap smear, with no 
gross lesions on cervix or vagina.
2. Persistence of inflammatory cells despite adequate treatment.
3. Persistence of keratinized cells
4. Evaluation of women who test positive for the visual screening tests: VIA and VILI
5. Evaluation of women who test positive for screening high risk HPV DNA test
6. Evaluation of women with postcoital bleeding, metrorrhagia and postmenopausal bleeding
7. Naked eye examination reveals unhealthy cervix or vagina suspicious of malignancy
8. Monitoring of women treated for CIN
9. Evaluation of women exposed to DES in utero
The most important part of colposcopy is identifying and visualising the SCJ in its entirety. The 
cervix is swabbed with 5% acetic acid solution followed by 50% Lugols iodine.
The colposcopic examination is unsatisfactory if the SCJ is not visualised in its entirety, the 
procedure is not possible because of constant bleeding from the friable epithelium, or the cervix is 
not visualized completely.(22)
COMBINED COLPOSCOPIC INDEX
Reid and Scalzi proposed a scoring system to predict the histologic diagnosis on the basis of four 
colposcopic features. In RCI, colposcopic signs, i.e., margins, colour , vascular patterns and iodine 
staining are graded into two objective categories; low grade CIN 1 or high grade CIN2 and CIN 3, 
combined into a single index called the Reids colposcopic index. (23)
REIDS COLPOSCOPIC INDEX (24)
Colposcopic 
sign
0 1 2
margin Condylomatous or 
micropapillary
Contour flocculated, or 
feathered
Jagged, angular, satellite 
lesion beyond TZ
Regular lesion with 
smooth borders
Rolled indistinct 
peeled edges
colour Shiny snow white, semi-
transparent opaque
Shiny grey-white 
intermediate
Dull oyster-white 
grey
vessels Uniform fine calibre, non-
dilated capillary loops
Absence of surface 
vessels
Definite 
punctuation and 
mosaic
iodine Positive iodine uptake Partial iodine 
uptake
Yellow staining 
lesion
Colposcopy score
0-2 HPV OR CIN 1
3-4 CIN1 OR CIN2
5-8 CIN 2 OR CIN 3      
HUMAN PAPILLOMA VIRUS 
Beral (1974) postulated that exposure to sexually transmitted infection is an important determinant 
of cervical cancer   .Zur Hausen(1991)suggested that HPV infection and HPV viral gene expression 
have emerged as necessary but not significant factors for cancer induction. Reviewing the 
epidemiological evidence linking HPV to cervical cancer, Bosch et al (1997) concluded that over 
90% of cervical cancer could be attributed to certain HPV types. The central role of HPV in 
cervical carcinogenesis has far reaching implications in prevention of this cancer.
MOLECULAR VIROLOGY OF HPV
HPV is a small double stranded DNA virus that is a member of the Papova virus group .The 
subtype of HPV are not serotype viruses but are genotypes in which the typing scheme is based on 
the similarity of one HPV type to the other known HPV types at the DNA level .The central HPV 
DNA repository is in Heidelberg and this facility assigns a new type if HPV after adequate 
studies .The viral genome of HPV consists of approximately 7900 nucleotides and all viral gene 
transcription occurs off one strand.
The HPV genome may be divided into three parts based on the function of the encode genes :the 
early E region E6,E7,E1,E2,E4,and E5 and the late L region.L1 L2and L3 and non –coding region 
which harbours the origin of replication and transcription control signals essential for the regulatory 
functions of the genome.
HPV genome is approximately 7900 bp in length The early (E) region of the genome is separated 
from the late (L) region by the long control region (LCR) that contains sequences involved in the 
regulation of expression of HPV proteins.
The viral genome DNA in fully formed viral particles is surrounded by a protein coat known as the 
viral capsid that consists of the (L) regions L 1 and L 2; The (E) region proteins are associated with 
cell transformation and viral gene regulation and are most critical in the pathogenesis of invasive 
cancer. Between (E) and (L) lies the LCR, which contains promoter and enhancer DNA sequences 
critical to viral gene transcription by both viral and cellular genes.
The specific HPV types exhibit a degree of tissue tropism. Some types such as HPV 1 and 2 are 
most found in the keratinized skin of the palms and soles in the form plantar and palmar warts .The 
types such as 6, 11, 16 and 18 are most found in the keratinized skin and the mucosal surfaces of 
the anogenital region including the cervix .Types 16 and 18 are considered to have a malignant 
phenotype as they exhibit a strong association with invasive cancer (Palafsky and Holly 1995).
DETECTION OF HPV INFECTION AND HPV GENOTYPES
Reliable and reproducible measurement of exposure is an important aspect of epidemiological 
investigations .In studying the relationship between HPV and cervical neoplasia ,it is not always 
possible to obtain tissue biopsies .A cytological finding of koilocytosis represents HPV infection 
but cytology cannot detect the larger percentage of infections at the DNA level .The limit of the 
earlier epidemiological studies was the lack of an appropriate method for assessing type specific 
HPV infection.
Serological methods were also used to study the HPV infection. Seroreactivity to HPV infection is 
a reflection of the cumulative exposure to HPV. It is also useful to use serological methods to study 
the transmission of HPV. High risk of seropositivity to HPV 16 with multiple sexual partners has 
been shown in studies (25).
The techniques of Southern, dot-blot and filter in situ hybridisation have suffered from problems of 
sensitivity and specificity, particularly when DNA extracted from cervical smears was examined 
(Munoz et al1988).The polymerase chain reaction (PCR) is an in vitro method for primer directed 
enzymatic amplification of specific target DNA sequences (Saiki et al 1988).PCR generates 
millions of copies of a specific DNA fragment in a few hours by in vitro enzymatic synthesis. HPV-
PCR consists of amplification of a targeted portion of the viral DNA and identification of the 
amplified product, PCR has been extensively used for HPV identification from exfoliated cells and 
biopsy tissues and for facilitating cloning and sequencing of HPV genomes. Stringent measures 
have to be adopted to avoid contamination of the specimen for PCR diagnosis. PCR has been 
shown to be more sensitive than filter in situ hybridisation and Southern blot analysis in the 
detection of HPV in cervical scrapes (Melchers et al 1989).
ETIOLOGICAL ROLE OF HPV IN CANCER CERVIX
Experimental studies have provided strong evidence that HPV is the long sought venereal cause of 
cervical neoplasia .A series of epidemiological studies with adequate exposure measurement in 
different settings have confirmed this finding.(Munoz et al 1994).
Prevalence of HPV DNA ranging from 22% to 100% have been reported in case series from 
different settings(IARC 1995).Bosch et al (1995) carried out a world wide prevalence study of HPV 
in cervical cancer in 1995.More than 1000 specimens from 22 countries were studied .HPV DNA 
was detected in 93% of tumours with no significant variation in HPV positivity among countries 
.HPV 16 was present in 50% of the specimens and HPV 18 in 14% of the specimens .These results 
confirmed the role of genital HPV in causation of cervical cancer .The etiological role of HPV and 
other risk factors in precancerous lesions of the cervix have been reviewed by Moorthy and 
Mathew(2000)
THE NATURAL HISTORY OF CERVICAL HPV INFECTION
Cervical carcinogenesis passes through well-defined entities as the changes occur in the 
epithelium .The age specific incidence of cervical dysplasia shows that it was most often diagnosed 
among women in their 20s, carcinoma in situ among those aged 30-39 years and invasive cancer 
after the age of 40 years (Canadian Task Force 1976)
Basal cells in the cervical epithelium rest on the basement membrane which is supported by the 
dermis. HPV is thought to access the basal cells through micro-abrasions in the cervical epithelium. 
Following infections the early HPV genes (E1, E2, E4, E5, E6 and E7) are expressed and the viral 
DNA replicates from the episomal DNA. In the upper layers of the epithelium (the mid-zone and 
the superficial zone) the viral genome is replicated further and the late L1 , and L2 and E4 are 
expressed.L1 and L2 encapsidate the viral genomes to form progeny virions in the nucleus. The 
shed virus can then initiate a new infection. Low grade intraepithelial lesions support productive 
viral replication. An unknown number of HPV viral infections progress to high grade intraepithelial 
neoplasia. The progression of untreated lesions to micro-invasive and invasive cancer is associated 
with the integration of HPV genome into the host chromosome with associated loss of disruption of 
E2 and subsequent up-regulation of E6 and E7 oncogene expression in LCR(long control region)
(26).
PERSISTENT HPV INFECTION
It is now widely believed that a persistent infection with a high risk HPV type is necessary for the 
development of high grade CIN and invasive cancer.
HPV INTEGRATION
HPV can be found in cervical material in episomal forms, integrated forms or in mixed forms that 
contains both viral integration into the host cell genome occurs downstream of the early genes E6 
and E7., often in the E1 or E2 region .This disruption results in the loss of a negative feedback 
control of oncogene expression by viral regulator E2 proteins .Integrant derived transcripts are 
more stable than those derived from episomal viral DNA and HPV 16 integration has been 
associated with selective growth advantage for affected cells (27).
HPV VIRAL LOAD
It is now clear that the relationship between the viral load and the disease varies with HPV types 
.For example cross sectional studies show that HPV 16 viral load increases with increasing disease 
severity ,whereas that of HPV 18 does not (28,29).
If the cytopathic effect observed in the exfoliated cells is a reflection of the viral load, then this 
might explain why the cytological changes detected after HPV 18 infection underestimate the 
severity of the underlying histological abnormality, unlike those detected after HPV 16 
infections(30).
EPIGENETIC CHANGES IN CERVICAL NEOPLASIA
Both viral and the host gene can be targeted by the cellular DNA methylation machinery .The 
pattern of methylation of the HPV genes varies with the viral life cycle, the presence of disease and 
possibly the viral type (31, 32, 33, 34).The denovo methylation of HPV DNA could be host defence 
mechanism for subsequent transcription of foreign DNA or a strategy that the virus uses to maintain 
a long term infection or both (35, 36) .
STAGES LEADING UPTO CERVICAL CANCER AFTER HPV INFECTION
HPV infection usually clears within a few months ;about 90%  of the infections clear within 2 
years(37).Persistence of infection beyond 12 months is associated with increased risk of cancer .It 
can  lead to moderate or severe CIN 2 or CIN3 or to adenocarcinoma in situ often grouped together 
as CIN2 or CIN 3 or AIS; which if untreated has a high probability of progressing to cancer(38).
HPV infects the basal layer of the epithelium. Most infections of the cervix are asymptomatic and 
the virus is cleared without treatment, median time for clearance is 8 months (39).More than 90% 
of the infections are cleared within 2 years (39,40,41,42). Early HPV infections may be 
accompanied by mild changes in the epithelium .An abnormal growth of the squamous cells of the 
cervix ,detected by cytological examination of the cervical smears is called a squamous 
intraepithelial lesion .The changes in cells are described as low grade (LSIL) or high 
grade(HSIL),depending on how much of the cervical epithelium is affected and how abnormal the 
cells appear .Equivocal changes seen on cervical smears are called atypical squamous cells or 
atypical glandular cells .Abnormal cells of the cervix detected by histological examination of the 
cervical biopsies are classified as cervical intraepithelial neoplasia (CIN).;They are graded from 
CIN1 to CIN3 according to the proportion of the cervix affected. The majority of LSIL or CIN1 
lesions disappear within a few months without treatment .If HPV infection persists however, it can 
lead to moderate or severe CIN2  orCIN3,or to adenocarcinoma in situ, which if untreated has a 
high probability of progressing to cancer.
CERVICAL CANCER
It refers to the malignant condition of the cervix.
SIGNS AND SYMPTOMS OF CANCER CERVIX
The early stages of cervical cancer may be completely asymptomatic. Patients are commonly 30 
years and above. In some developing countries like Uganda, it has been noted that younger women 
are reporting to health facilities with advanced disease of cervix compared to previous years .This 
has been attributed to immune suppression from HIV or AIDS .The common symptoms for cancer 
of cervix include:
 Intermenstrual bleeding
 Postcoital per vaginal bleeding
 Abnormal per vaginal discharge which tends to be foul smelling
 Lower abdominal pain ,backache are symptoms for advanced diseases due to the 
infiltration of cancer to involve nerves of the sacral plexus
 Leakage of urine or stool incontinence may occur when the cancer has advanced to stage 
4 disease to involve the urinary bladder and rectum respectively.
NB: It is very important to do a vaginal and a speculum examination to be able to look at the 
cervix .Its important to have a good source of light when looking at the cervix.
CAUSES
HPV infection
The most important risk factor in the development of cervical cancer is infection with a high risk 
strain of HPV. The virus cancer link works by triggering alterations in the cells of the cervix.
More than 150 types of HPV are acknowledged to exist. Of these 15 are classified as high risk 
types (16,18,31,33,35,39,45,51,52,56,58,59,68,73,and 82), 3 as probable high risk (26,53,66) and 
12 as low risk (6,11,40,42,43,44,54,61,70,72,81,CP6108) (43), but even those may cause cancer. 
Types 16 and 18 are generally acknowledged to cause about 70% of the cervical cancer cases. 
Together with type 31, they are the prime risk factors for cervical cancer (44).
OTHER FACTORS THOUGHT TO BE ASSOCIATED WITH CANCER 
CERVIX
Marital and sexual factors
The epidemiologists have noted that risk of cervical cancer is strongly influenced by sexual 
behaviour. This has led to the discovery of role HPV infection. Studies have shown increased risk 
due to marriage at young age, onset of regular sex at an early age<20 years, multiple lifetime no. of 
sexual partners(45).These risk factors remain significant especially among those women without 
apparent HPV infections.
Role of male sexual partners
In most studies the husbands of cervical cancer patients were found to report more sexual partners, 
history of various genital infections like venereal warts, gonorrhoea and herpes simplex genitalis 
compared to husbands of control subjects. Frequent use of condoms was associated with a lower 
risk for cancer cervix (46).
Gynaecological and obstetric events
Multiparity with short intervals between pregnancies(<2 years) has been consistently shown to 
increase the risk of SIL and cervical cancer(47).There is little evidence to show that the risk of 
cervical cancer is affected by age at menarche and menopause, characteristics of menses and 
personal hygiene(48).
Contraceptive methods
Recent research is showing that long term users of oral contraceptives are at excess risk for cervical 
cancer, even after adjusting for sexual and social factors. The risk may be stronger for 
adenocarcinoma than squamous cell neoplasm (48) Regular users of barrier methods of 
contraception (condom or diaphragm) have been found to have lower risk of cervical cancer (49).
Genetic factors
Although some reports suggest that a familial tendency does exist, but there is still little attention to 
it (50).
Dietary factors
Micronutrients are thought to have a protective effect on cervical cancer, by promoting the 
regression of low grade intraepithelial lesion. Some components of fruits and vegetables have been 
suggested to be protective too (51).
Smoking
Some case control studies and a cohort investigation have demonstrated  increased risk of cervical 
cancer and SIL among smokers even after controlling for most other risk factors. However the 
smoking effect is restricted to squamous cell carcinoma and not among other histological types 
(52).
Infections other than HPV 
HSV-2 and chlamydiae have been shown to increase the risk (53).One of the studies conducted in 
Uganda showed an increased risk of cervical cancer with multiple and concurrent infections, thus 
addressing the hypothesis that chronic cervicovaginal infections may increase the risk of HPV (54). 
COMPLICATIONS OF CANCER CERVIX
The common ones include:
 severe anaemia as a result of severe or chronic on and off bleeding from the cervix
 renal failure due to obstruction of the ureters by the infiltrating cancer 
 lymphoedema due to the blockage of lymphatic drainage leading to swelling of the 
lower limbs 
 vesicovaginal and rectovaginal fistula
 severe pain as a result of infiltration of the sacral nerves
 mortality is commonly due to anaemia and uraemia
DIAGNOSIS
Biopsy procedures
Confirmation of the diagnosis of cervical cancer or pre-cancer requires biopsy of the cervix. This is 
done through colposcopy, using VIA to highlight the abnormal cells on the surface of the cervix or 
a punch biopsy in a frank carcinoma (55).
PATHOLOGIC TYPES
Histologic subtypes of invasive cervical carcinoma include the following (56, 57).Though 
squamous cell carcinoma is the cervical cancer with the most incidence ,the incidence of 
adenocarcinoma of the cervix has been increasing in the recent decades(57).
1. Squamous cell carcinoma (about 80-85%)
2. Adenocarcinoma(about 15% of cervical cancers in UK)
3. Adenosquamous carcinoma
4. Small cell carcinoma 
5. Neuroendocrine carcinoma
STAGING
Cancer cervix is staged by the International Federation of Gynaecology and Obstetrics (FIGO) 
staging system, which is based on clinical examination, rather than surgical findings. It allows only 
the following diagnostics tests to be used in determining the staging: inspection, palpation, 
colposcopy, endocervical curettage, hysteroscopy, cystoscopy, proctoscopy, intravenous urography, 
and X ray examination of the lungs and skeleton and cervical conisation.
The TNM staging system for cervical cancer is analogous to the FIGO staging
Stage 0-full thickness involvement of the epithelium without invasion into the stroma (carcinoma 
in situ)
Stage 1-limited to cervix
1A-diagnosed only by microscopy; no visible lesions
1A1- stromal invasion <3mm in depth and 7mm or less in horizontal spread
1A2- stromal invasion between 3 and 5 mm with horizontal spread of 7 mm or less
1B –visible lesion or microscopic lesion with more than 5 mm of depth or horizontal spread of 
more than 7 mm
1B1-visible lesion 4cm or less in greatest dimension
1B2- visible lesion more than 4cm
Stage 2- invasion beyond the cervix
11A- Without parametrial invasion, but involves the upper 2/3rd of the vagina
11A1-clinically visible lesion less than or equal to 4 cm in greatest dimension
11A2-clinically visible lesion more than 4 cm in greatest dimension           
11B- with parametrial invasion
Stage 111-extends to pelvic wall or lower 1/3 of vagina
111A-involves lower third of vagina
111B- extends to pelvic wall or causes hydronephrosis or non-functioning kidney
Stage 1V-spread to pelvic organs or distal metastasis
 1VA- invades mucosa of bladder or rectum and or extends beyond true pelvis
1VB-distant metastasis
TREATMENT
Microinvasive cancer cervix (stage 1A) is usually treated by hysterectomy. For stage 1A2, the 
lymph nodes are removed as well. An alternative for patients who desire to remain fertile is a local 
surgical procedure such as loop electrical excision procedure (LEEP) or cone biopsy (58).If cone 
biopsy does not produce clear margins one more possible option is a trachelectomy (59).
Early stages (1B1 and 11A <4cm) can be treated with radical hysterectomy with removal of the 
lymph nodes or radiation therapy. Radiation therapy is given as external beam radiotherapy to 
pelvis and brachytherapy (internal radiation)
Larger early stage tumours (1B2 and 11A >4cm) may be treated with radiotherapy and cisplatin 
based chemotherapy, hysterectomy, or cisplatin chemotherapy followed by hysterectomy.
Advanced stage tumours (11B-1VA) are treated with radiation therapy and cisplatin based 
chemotherapy.
PREVENTION
Awareness
According to the US National Cancer Institute s 2005 Health Information Trends survey, only 40% 
of American women surveyed had ever heard of HPV infection only 20% have heard of its link to 
cervical cancer (60).
SCREENING
The widespread introduction of the Papanicolaou Test for cervical cancer screening has been 
credited with dramatically reducing the incidence and mortality of cervical cancer in developed 
countries.(61).Recommendations for how often a pap smear should be done varies from once a year 
to once every 5 years. The ACS recommends that cervical cancer screening should begin 
approximately 3 years after the onset of vaginal intercourse and or no later than 21 years of age 
(62).Guidelines vary on how long to continue screening ,but well screened women who have not 
had abnormal smears can stop screening at the age of 65 to 70 (ACS).
Liquid based cytology has been incorporated within the UK national screening programme. Its 
main advantage has been to reduce the number of inadequate smears from 9% to around 1% (63).
The HPV test is newer technique for cervical cancer triage which detects the presence of HPV 
infection in the cervix. It is more sensitive than Pap smear, but less specific and its role in routine 
screening is still evolving. Since more than 99% of invasive cervical cancers worldwide contain 
HPV, some researchers recommend that HPV testing be done together with routine cervical 
screening (64).
PREVENTIVE VACCINATION
Gardasil, licensed and manufactured by Merck and Co. is a vaccine against HPV types 6, 11, 16, 
and18. Gardasil is upto 98% effective (65).It is now on the market after receiving approval from the 
USFDA on June 8, 2006(66). Gardasil has also been approved in the EU (67).
Glaxo Smithkline has developed a vaccine called Cervarix which has shown to be 92% effective in 
preventing HPV strains 16 and18 and is more effective for more than 4 years (68).
HPV vaccines are targeted at girls and women of age 9-26 because the vaccine only works if given 
before infection occurs. The high cost of this vaccine has been a cause for concern.
CONDOMS 
They offer some protection against cervical cancer (69).
SMOKING AVOIDANCE
Carcinogens from tobacco increase the risk for many cancers including cervix cancer and women 
who smoke have double the risk of a non-smoker to develop cervical cancer.
NUTRITION
Fruits and vegetables
High levels of vegetable consumption were associated with a 54% decreased risk of HPV 
persistence (70).
Vitamin E
HPV clearance  time was significantly shorter among women with the highest compared to lowest 
serum levels of tocopherols, but significant trends in these association were limited to infections of 
about 120 days(71).
Folic acid
Improving folate status in subjects at risks of getting infected or already infected with high risk 
HPV may have a beneficial impact in the prevention of cervical cancer (72, 73).
PROGNOSIS
Prognosis depends on the stage of the cancer. With treatment, the 5 year survival rate for the 
earliest stage of invasive cancer is 92% and the overall (all stages combined) 5 year survival rate is 
about 72% (74).
With treatment, 80 to 90% of women with stage 1 cancer and 50 to 65 % of those with stage 11 are 
alive 5 years after diagnosis. Only 25 to 35% of   women stage 111 cancer and 15% or fewer of 
those with stage 1V cancer are alive after 5 years (75).
According to the FIGO, survival improves when radiation therapy is combined with cisplatin based 
chemotherapy (76).
AIM OF THE STUDY
The aim of the study is to determine   the prevalence of high risk human papilloma viruses 16 and 
18 in women with symptoms of chronic discharge per vaginum and those with cancer cervix 
attending our Gynaecology OPD.
MATERIALS AND METHODOLGY
SETTING OF THE STUDY
The study was conducted at the Institute of Obstetrics and Gynaecology, Egmore in collaboration 
with the Department of Biotechnology, Cancer Biology Lab, IIT, Chennai between 2008-2009.
STUDY DESIGN AND POPULATION
It is a hospital based study .300 Consenting women attending the Gynaecology OPD at our Institute 
were enrolled with 100 cases belonging to the symptomatic group and 100 belonging to cancer 
cervix and 100 cases who came to the OPD for other complaints.
INCLUSION CRITERIA
The women with the following criteria were included in the symptomatic group in our study
1. Age 16 to 70 years
2. Patients with complaints of persistent vaginal discharge.
3. Patients with complaints of intermenstrual or postcoital bleeding
4. Unhealthy cervix per speculum
Simultaneously 100 women with frank carcinoma cervix and 100 women who attended the 
Gynaecology OPD for other complaints who underwent total Hysterectomy due to complaints other 
than uterine cervical lesions such as uterine fibroid, endometriosis and so on were also studied for 
HPV prevalence.
EXCLUSION CRITERIA
The women fulfilling the following criteria were excluded from the study
1. Pregnant women and puerperium
2. Women with bleeding at the time of examination
3. Clinical evidence of acute infection
4. Unsatisfactory colposcopy
5. Unmarried women
6. Women undergoing radiotherapy or chemotherapy for cancer cervix
7. Women with cancer cervix recurrence
CONSENT AND ETHICAL CONSIDERATIONS
A written informed consent in local vernacular was obtained from each patient prior to enrolment in 
the study .Ethics Committee of the Institution approved the study protocol.
METHODOLOGY
Relevant socioeconomic, obstetric, gynaecological, and medical history was obtained in a pre-
tested, semi structured questionnaire.
SPECIMEN COLLECTION IN SYMPTOMATIC WOMEN
Women with chronic discharge were examined under illumination per speculum, gross naked eye 
findings were noted and cases selected after considering the Pap smear report of inflammatory 
smear. Pap smear was taken by Ayre’s spatula by rotating through 360 degrees across the 
squamocolumnar junction so as to obtain the representative samples. The smear was fixed in 
absolute alcohol. Cervical abnormalities identified by visual inspection with acetic acid or 
abnormal cytology were referred to colposcopy. Visible lesions identified by colposcopy were 
biopsied. A final diagnosis of CIN was assigned to each woman based on the review of cytology 
and histology.                    
Colposcopic index method: Using the colposcope the cervix was visualised under low power to 
note any abnormal findings. Capillaries and surface blood vessels of the cervix were examined with 
green filter. Freshly prepared 5% glacial acetic acid was gently applied twice over the cervix to 
ensure acetowhite reaction followed by visual inspection with Lugols Iodine using 50% iodine. 
Transformation zone was defined both at the proximal and distal ends. Colposcopy was considered 
unsatisfactory if the squamocolumnar junction was not visualised completely and advised 
endocervical curettage. In case of satisfactory colposcopy, the cervix was divided into 4 quadrants 
by an imaginary line passing through the centre from 6o clock to 6o clock and 3o clock to 3o clock. 
Examination of each quadrant was done in clockwise direction beginning from right upper 
quadrant. Acetowhite reaction was seen in the transformation zone; the margin, colour, vessels, and 
colposcopy signs were scored using RCI Scoring method and recorded. Colposcopic guided 
biopsies were taken with punch biopsy forceps from the site with the highest score. The tissue was 
immediately transferred to a vial containing 10% formaldehyde and sent for histopathological 
examination and a part of it was collected in RNA Later solution for HPV testing. Pressure was 
applied to the sites to control bleeding. Women were counselled for follow-up and genital hygiene. 
They were reviewed with cytology and histopathological reports were compared and further 
management was advised according to guidelines for CIN or CIS.
EVALUATION OF CERVICAL INFLAMMATION 
Cervical inflammation was assessed by counting the number of neutrophils observed in microscope 
fields on Pap slides from each study subject. Enrolment Pap-stained smears were evaluated at x400 
initially to identify cervical mucus. Smears having no identifiable cervical mucus were considered 
invalid for evaluation because of uncertainties related to sampling adequacy. Valid slides were 
observed at x1000 to identify neutrophils, identifiable by their multilobed nuclei. The numbers of 
neutrophils were counted in five nonadjacent fields not contaminated by squamous epithelial cells, and 
were averaged and scored as no inflammation (0–5 neutrophils/field), intermediate inflammation (6–30 
neutrophils/field), and cervicitis (More than 30 neutrophils/field). 
Importantly, to minimize bias, readings of Pap slides for cytopathology were done independently of the 
blinded assessments for Nugent score/ neutrophils by collaborators who are not trained to evaluate 
cytopathology of cervical cells
SPECIMEN COLLECTION IN WOMEN WITH FRANK CERVICAL CANCER
All 100 cases underwent the standard procedures to confirm the diagnosis of cervical cancer and 
establish the stage of the disease as per standard of care in the centre. Staging was based on 
International Federation of Obstetrics and Gynaecology criteria. During clinical examination, two 
small pieces of tissues were taken from the tumour using punch biopsy forceps, one sample sent for 
histopathological examination and the other sample collected in RNA later solution for HPV DNA 
testing.
SPECIMEN COLLECTION IN WOMEN WITH OTHER COMPLAINTS 
In Women with other complaints the cervical tissue samples were obtained from theatres posted for 
fractional curettage, after verifying the basic screening report.
DEFINITION OF A POSITIVE RESULT
Cytology reports were reported as positive when more than 30 neutrophils were detected per high 
power field. VIA was considered to be positive if definite acetowhite lesions were visualized closed 
to the squamocolumnar junction or if the entire cervix or growth of the cervix turned acetowhite. 
VILI was considered to be positive if yellow, iodine non-uptake areas were visualized close to the 
squamocolumnar junction, or if the entire cervix or growth on the cervix turned yellow.
HPV DNA TESTING
On enrolment, cervical tissue samples of the selected participants were assayed for HPV DNA 
using the Reverse Transcriptase Polymerase Chain Reaction (RT-PCR). All samples were assayed 
for HPV DNA using a more sensitive PCR-based L1 consensus primer HPV test (18, 19). cDNA 
synthesized were tested for HPV by PCR using MY09/MY11 L1 consensus primers with primers 
for GAPDH as the internal PCR control. Valid PCR results were obtained from 300 samples. 
Amplified DNA was separated by electrophoresis, and HPV DNA was detected by Ethidium 
bromide staining.
RNA ISOLATION:
Trizol reagent from GIBCO BRL
It is a ready to use reagent for the isolation of total RNA from the cells and tissues. During sample 
homogenization or lysis, it maintains the integrity of the RNA, while disrupting cells and dissolving 
cell components.                      
REAGENTS REQUIRED
 Chloroform
 Isopropyl alcohol
 75% Ethanol (in DEPC-treated water)
 RNAse-free water or 0.5% SDS solution [To prepare RNAse-free water, draw water into 
RNAse-free glass bottles. Add diethylpyrocarbonate (DEPC) to 0.01% (v/v). Let stand 
overnight and autoclave. The SDS solution must be prepared using DEPC-treated, 
autoclaved water.
1. HOMOGENIZATION 
Tissues
Homogenized tissue samples in 1 ml of TRIZOL® Reagent per 50-100 mg of tissue using a glass-
Teflon® or power homogenizer (Polytron, or Tekmar's TISSUMIZER® or equivalent). The sample 
volume should not exceed 10% of the volume of TRIZOL® 
Reagent used for homogenization.
2. PHASE SEPARATION
Incubated homogenized samples are kept for 5 minutes at 15 to 30°C to permit the complete 
dissociation of nucleoprotein complexes.  0.2 ml of chloroform per 1 ml of TRIZOL® Reagent is 
added. Tubes were shaken vigorously by hand for 15 seconds and incubated at 15 to 30°C for 2 to 3 
minutes. The samples are centrifuged at no more than 12,000 × g for 15 minutes at 2 to 8°C. Following 
centrifugation, the mixture is separated into a lower red, phenol-chloroform phase, an interphase, and a 
colourless upper aqueous phase. RNA remains exclusively in the aqueous phase. The volume of the 
aqueous phase is about 60% of the volume of TRIZOL® Reagent used for homogenization.
3. RNA PRECIPITATION
The aqueous phase was transferred to a fresh tube, and precipitated the RNA from the aqueous phase 
by mixing with isopropyl alcohol. Use 0.5 ml of isopropyl alcohol per 1 ml of TRIZOL® Incubated 
samples at 15 to 30°C for 10 minutes and centrifuged at no more than 12,000 × g for 10 minutes at 2 to 
8°C. The RNA precipitated, often invisible before centrifugation, forms a gel-like pellet on the side and 
bottom of the tube.
4. RNA WASH
The supernatant was removed and the RNA pellet was washed once with 75% ethanol, adding at least 1 
ml of 75% ethanol per 1 ml of TRIZOL.The sample is mixed by vortexing and centrifuged at no more 
than 7,500 × g for 5 minutes at 2 to 8°C. 
5. REDISSOLVING THE RNA 
At the end of the procedure, the RNA pellet was briefly dried (air-dry or vacuum-dry for 5-10 minutes). 
It is important not to let the RNA pellet dry completely as this will greatly decrease its solubility. 
Partially dissolved RNA samples have an A260/280 ratio < 1.6. Dissolve RNA in RNAse-free water or 
0.5% SDS solution by passing the solution a few times through a pipette tip, and incubating for 10 
minutes at 55 to 60°C. 
SYNTHESIS OF CDNA USING REVERSE TRANSCRIPTASE ENZYME
 10µL of RNA was taken in a 0.5ml PCR tube and RT-PCR reaction mixture was added as 
follows:
REACTION MIX
5X Buffer : 10 µL
MgCl2     : 2 µL
dNTP      : 4 µL
oligo dT  : 2 µL 
MMLV RT : 1 µL 
RNA         : 10 µL
Water : 15 µL
RNAse Out : 0.4 µL
 The above reaction was run using following programme
Table 2: Represents the Reverse Transcriptase Program
Add RNA+Primer+Water mix
T=700C 5 minutes
Pause  Add dNTPs, DTT, RT Buffer (5X), RNAse inhibitor, Water, MMLV RT 
reaction mix
T=370C 5 minutes
T=370C 1 hour
T=950C 5 minutes
Hold 40C  forever
POLYMERASE CHAIN REACTION
Polymerase Chain Reaction was set up in an Eppendorf thermocycler (Mastercycler Personal) as 
follows:
10X buffer : 1.2 µL
MgCl2 : 0.4 µL
dNTP : 0.2 µL
Taq polymerase : 0.2 µL
Forward primer : 0.8 µL
Reverse primer : 0.8 µL
Water : 12 µL
The above reaction was run using the following PCR program:
Step 1: 95ºC : 5min
Step 2: 94 ºC : 1 min.
Step 3: 58 ºC : 1 min (appendix)
Step 4: 72 ºC : 1 min
Step 5: Go to : Step 2   : Repeat the cycle 35 times.
Step 6: 72 ºC : 10 min
The PCR product was checked on 1% Agarose gel in TAE.
Table 1:  Primers Used
PRIMER/
Predicted Base 
Pair Size (bp)
SEQUENCE Annealing temperature
GAPDH
(588)
Sense
Antisense
CCA CCC ATG GCA AAT 
TCC ATG GCA
TCT AGA CGG CAG GTC 
AGG TCC ACC
62°C
HPV16
(450)
Sense
Antisense
AAA CAG ATG AAG TGC 
TCC TTC CAG G
TGG AGA ACA CCA CTT 
GTT GCT CCA
58°C
HPV18
(450)
Sense
Antisense
CGG GAC GTG GAG CTG 
GCC GAG GAG
CAC CAG CTG GTT ATC 
TCA CAG CTC
58°C
RESULTS
Total Population
This study had a total population of 300 women who attended our gynaecology OPD with 100 women 
belonging to the symptomatic group, 100 women belonging to group of women who attended the op 
for other complaints and 100 women who had frank carcinoma cervix.
Per speculum examination was done and Pap smear examination was done followed by coloposcopy 
guided biopsy in the symptomatic group while in women with frank carcinoma cervix a punch biopsy 
was taken from the cervical growth in women who attended the OPD for other complaints and who 
where posted for fractional curettage, the cervical biopsy sample was collected from the theatre .All 
these samples were tested for high HPV 16 and 18 using RTPCR 
The mean age of the study population was 44.77 years with a standard deviation of 10.2
DISTRIBUTION OF HPV PREVALENCE IN EACH GROUP
SOCIO DEMOGRAPHIC CHARACTERISTICS OF WOMEN, CORRELATED 
WITH HIGH RISK HPV TYPE 16 PREVALENCE
1. AGE WISE DISTRIBUTION OF HPV 16 PREVALENCE         
Age wise distribution of HPV 16 prevalence
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HPV 16 prevalence in symptomatic group was maximum in the age group of 31 to 40 years and with a 
prevalence of 68% in the same .In women with other symptoms the over all HPV prevalence was 
19% .The prevalence in CA cervix group did not show significant variation with age 
2. AGE AT MARRIAGE AND HPV 16 PREVALENCE
Age at Marriage and HPV 16 Prevalence
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The median age at marriage was 19 years with a standard deviation of 1.85. Women with marriage at 
an early age had a higher prevalence of HPV infection. In symptomatic women, the prevalence was 
found maximum in the age group of less than 17 years which was 80% whereas that in women with 
other symptoms was 33.3%.The prevalence in ca cervix group did not show significant variation with 
age at marriage.
3. AGE AT FIRST COITUS AND HPV 16 PREVALENCE
Age at first Coitus and HPV 16 Prevalence
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The median age at first coitus was 19 years with a standard deviation of 1.85. Women with coitus at an 
early age had a higher prevalence of HPV infection. In symptomatic women, the prevalence was found 
maximum in the age group of less than 17 years which was 80% whereas that in women with other 
symptoms was 33.3%.The prevalence in ca cervix group did not show significant variation with age at 
first coitus.
4. PARITY AND HPV 16 PREVALENCE                        
Parity and HPV 16 prevalence
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Number of pregnancies among the 3 study groups was unrelated to HPV 16 positivity
5. EDUCATIONAL STATUS AND HPV 16 PREVALENCE
Educational Stauts and HPV 16 prevalence
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The distribution of educational status of the 300 women is given the following table.
Educational status Symptomatic women Cancer cervix Women with Other symptoms
Illiterate 34% 36% 27%
Primary school 12% 36% 43%
Middle school 21% 24% 20%
High school and 
bove 33% 14% 10%
70% of the study population were illiterate or had only primary level education. The prevalence of 
HPV 16 was higher in illiterate and primary education group when compared to those who had middle 
or higher education. In index population the prevalence of HPV 16 in illiterate group was 73.5% while 
in women with other symptoms it was 14%.In illiterate women with ca cervix the same was found to be 
100%.
6. SOCIOECONOMIC STATUS AND HPV 16 PREVALENCE  
Socio Economic Status and HPV 16 prevalence
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Women belonging to lower socioeconomic status had a higher risk of HPV 16 infection than those 
from medium or high socioeconomic group in the study.
CARCINOMA CERVIX AND HPV 16 AND 18 PREVALENCE
The prevalence of hpv 16 and 18 in cancer cervix was 97% and 32% respectively. The prevalence of 
hpv 18 was more with early age at marriage and early age at first coitus. It was also high in the women 
belonging to lower socioeconomic status
Age at marriage(years) HPV 16 positivity HPV 18 positivity
<17 100% 17.6%
18-20 98.3% 40%
>=21 91.3% 21.7%
STAGEWISE DISTRIBUTION OF CANCER CERVIX 
Most of the women with ca cervix in the OPD presented with late stage, 11B and above. Women with 
early stage comprise 25% of the total group and those with late stage comprise 75% of the total group.
Distribution of FIGO staging of cancer cervix
75%
25%
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STAGEWISE HPV 16 PREVALENCE IN CANCER CERVIX
Prevalence of hpv infection in early stage was 96% and in the late stage was 97%
PAP SMEAR AND HPV 16 PREVALENCE 
Pap Smear distribution in symptomatic women
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S.No Report Hpv 16 Prevalence
1 inflammatory 64%
2 LSIL 100%
3 HSIL 100%
4 ASCUS 100%
HPV 16 prevalence in women with inflammatory smear was 64% while dose with pap smear report 
showing LSIL, HSIL and ASCUS showed a 100% positivity.
TNF ALFA IN SYMPTOMATIC WOMEN 
Distribution of TNF Alfa fold increase in 
symtomatic women
43%
36%
21%
P +
P ++
P +++
It was found to be increased in symptomatic women and 100% positive in HPV 16 infection .The 
increase in expressions of TNF alpha was not associated with intensity of HPV infection .In this study 
we attempted to analyse TNF levels in peripheral blood mononuclear cells (PBMC) of chronic 
cervicitis and squamous cell carcinoma patients. Our results implicated increased TNF levels in chronic 
cervicitis patients representing their hyper immune response whereas SCC patients showed a 
low/completely absent TNF expression indicating their immunocompromised status when compared to 
normal levels. 
DISCUSSION
HPV infection is recognised as a public health problem for its role as a critical factor in the 
pathogenesis of various cancers. Cervical cancer is a preventable disease. It develops following the 
progression of uncleared HPV infection to high grade and eventually to invasive disease. Women with 
normal cervical cytology who are infected with high risk HPV, have an approximately 100 fold 
increased risk of developing CIN 3, compared with uninfected women. Persistence of oncogenic HPV 
appears essential for the development of cervical neoplasia. With the advent of molecular techniques 
particularly PCR, it is possible to detect very low quantities of HPV and to subtype the commonly 
occurring HPV in cervical specimens. The cytologic features of the conventional Pap smears have 
restricted value in identifying women destined to develop cervical neoplasia. The ALTS study group 
(Atypical Squamous cells of Unknown Significance- low grade squamous intraepithelial triage study) 
aimed at resolving the issue of management of low grade cervical lesions. They concluded that women 
with less than cervical intraepithelial neoplasia2(CIN2) status at initial colposcopy remain at risk for 
subsequent CIN2 +.Follow-up HPV testing is significantly more sensitive than cytology for detecting 
missed prevalent cases. In the same study, few cases of CIN3 had a negative HPV testing, which 
reinforces the fact that even the most sensitive test cannot provide perfect assurance. Thus HPV testing 
should be used as an adjunct to Pap smear.
     There is ample data on prevalence of HPV in women with cervical cancer, however data on HPV 16 
and 18 prevalence in symptomatic women with clinically abnormal cervix from India is sparse. HPV 
16 and 18 are more prevalent in this part of the world. Type of HPV in primary screening depends upon 
the population being screened. Clifford et al (77) have suggested that cost effective test could include 
subset of high risk HPV, which are most likely to progress to cancer.  The prevalence of HPV 16 in the 
index population in our study was found to be 64%.Aggarwal et al (78) reported a HPV prevalence in 
the same group as 14.2%.Dutta gupta et al (79) also reported a prevalence of 8.8% in the index study. 
Two large population based studies in cytologically normal women, Sankaranarayanan et al (80) 
reported 10.3% high risk HPV detection using HC2 in Osmanabad district in West India. Somewhat 
similar estimate was reported by HC2 in a separate multicentric study in Mumbai (6.3%) and 
Trivandrum 7.8 %( 81) .Soujanya et al (82) in their study showed a HPV 16 prevalence of 10. 4%.The 
higher prevalence in women attending our Gynaecology OPD may be plausibly attributed to the fact 
that our Institute is the highest referral centre for the surrounding Government hospitals and primary 
health centres and that most subjects come here after having taken treatment at several centres and that 
we targeted women in the high risk group viz, women with chronic vaginal discharge. The probable 
incrementing factor for the high prevalence of HPV in our study might be the illiteracy and low 
socioeconomic status of most of the subjects who attended our Gynaecology OPD.
Most prevalent HPV genotype in the symptomatic women was HPV 16. However screening of a larger 
sample in our hospital will give a better picture on the distribution of HPV genotypes.
In women with other symptoms, the prevalence of HPV 16 was only 15%.Aggarwal et al had reported 
an estimated prevalence of 7.4% in the same group in their study. 
Women with cancer cervix showed a HPV 16 prevalence of 97% and HPV 18 prevalence of 32%.High 
risk HPV infection was demonstrated as an indicator of malignant lesions like cancer cervix with a 
magnitude of 84% by Riou et al and 90% by Zur Hausen.Berlin (83, 84, 85) grace et al observed a 
highly significant association between high risk HPV 16 and 18 infection and development of cervical 
cancer (P=0.0001). Their data showed that HPV 16 was the most prevalent type in cervical lesions , 
especially cancer cervix.Soujanya Jain et al in their study showed that the most prevalent HPV types 
found in invasive cancer cervix in Andhra Pradesh was HPV 16(66.7%),followed by hpv 18 (19.4%). 
In another case control study in Southern India, it is reported HPV prevalence as high as 99.4% in their 
invasive cancer group. The difference in the results may be due to the fact that this is a hospital based 
study with facilities for the treatment of cancer cervix by radiotherapy and that women in our study 
mostly presented to us in the late stage of cancer cervix. Therefore we can confirm, that a vaccine 
targeting HPV 16 could eliminate >50% of the cervical cancer burden in Tamilnadu, as well as South 
India. More comprehensive genotyping of cervical cancer tissues from North, West, and Northeast 
India will be needed to justify a single national vaccine strategy for the Indian subcontinent. 
We found that the prevalence of HPV 16 in the symptomatic women was highest in the age group 
between 31-40 years. This coincides with the peak incidence of invasive cancer cervix at 35 years, the 
next peak at about 50-55 years. But no significant age related difference was noted in Aggarwal et al 
study. The HPV prevalence in the same age group was reported as 7.1%. Dutta Gupta et al also made 
similar observations of HPV 16 prevalence among Muslim women. Chaouki et al (86) also reported no 
significant age related difference .This difference in our study can be attributed to the fact that our 
Institute is the highest referral centre with the women coming to us after getting treatment at various 
centres.
Women who got married at an early age showed a higher prevalence of HPV 16(80%) in the 
symptomatic group. The age specific incidence of cervical dysplasia shows that it was most often 
diagnosed in women in their 20s (Canadian Task Force).Women are prone to HPV infection with   the 
beginning of sexual intercourse. HPV 16 is the most common type in women with normal cytology. 
The results in our study showed that most women were infected by HPV as they started their sexual 
activity earlier. Aggarwal et al reported a prevalence of 8.6% in their study. Dutta gupta et al did not 
find any association of HPV 16 with the age of consummation of marriage.
Women who were illiterate or had <6 years of education had a significantly higher prevalence of HPV 
16, 73% and 56% respectively in the index population. Aggarwal et al also reported a higher rate of 
HPV with a positivity of 13.1%.This very well supports the fact that cervical cancer is more prevalent 
in the less educated population reflecting their practices regarding genital hygiene.
Women belonging to a lower socioeconomic status had a higher prevalence of HPV 16 in the index 
study about 70.7% and in women with cancer cervix, it was 97%. Aggarwal et al also reported a higher 
rate of high risk HPV infection of 11.8% than those from medium or high socioeconomic group, 
although the difference was not statistically significant. Franceschi et al (87) has recognised low 
socioeconomic status as a risk factor for cervical carcinoma as well.
There was no significant parity related difference in the index study in the distribution of HPV. 
Aggarwal et al reported that more number of women 10.8% with 3 or more children were positive for 
high risk HPV as compared to those with less than 3 children (6%). The difference was however not 
statistically significant. Dutta gupta et al and Laczano et al (88) too did not observe any significant 
association of HPV 16 or 18 with parity.
SUMMARY
This study was conducted in our Institute which comprises women attending the Gynaecology OPD for 
various reasons. 300 consenting women were enrolled with 100 belonging to the group of women who 
came with complaints of persistent vaginal discharge, 100 women who came for other complaints and 
100 women with frank cancer cervix. A Pap smear was obtained in the index study and colposcopic 
guided biopsy of the cervical tissues was also obtained. Cervical tissue samples in subjects who 
underwent total hysterectomy due to complaints other than uterine cervical lesions such as uterine 
fibroids, endometriosis and so on, were obtained from theatres posted for fractional curettage after 
verifying the basic screening report .Cervical punch biopsy samples were taken in 100 women who 
came with frank cancer cervix.
Cervical tissue samples were stored and Reverse Transcriptase Polymerase chain reaction (RT-PCR) 
was done to assay HPV DNA16 and 18. The prevalence of HPV 16 and 18 in each of the groups was 
analysed. We found that the prevalence of HPV 16 in the index study, in women with other symptoms 
and those with cancer cervix was 63%, 15%, and 97% respectively. HPV 18 prevalence in cancer 
cervix was 32%.HPV 16 prevalence was highest in the age group 30 – 40 years It was also high in 
women who got married at an early age, women belonging to the lower socioeconomic strata, and in 
the illiterate group. We did not observe any significant parity related difference in HPV 16 prevalence.
The index study generated the prevalence data of subclinical high risk HPV infection in the 
symptomatic women. The limitation of the study is that being a hospital based study, the women 
enrolled visited the hospital with varied ailments and thus were not true representations of the 
community. In addition, the prevalence of high risk HPV, other than hpv 16 AND 18 was not 
evaluated.
Cancer cervix screening practices are inconsistent in India. Use of Pap smear, as a sole indicator for 
screening has limitations. The cytological interpretation becomes faulty if the smear is inflammatory, a 
situation not infrequent among women from the lower socioeconomic background. In a scenario of 
infrequent screening, screening with a test of high sensitivity provides greater reassurance, that 
potential disease has not been missed in women who screened negative. It is an irony that the middle 
and high socioeconomic women, who can afford HPV screening by molecular techniques require it the 
least, owing to the low prevalence. High risk HPV DNA screening appears to be a valid option in mass 
cervical screening programmes in the developed countries. In a resource poor country, it is not feasible 
to offer a universal molecular testing for high risk HPV, till HPV screening is made cheaper. 
Identification of population at risk will enable focused screening, with a greater cost effective 
utilization of resources. Screening preferentially should be directed to the target population for the 
optimal utilization of resources. Needless to say, health education, promotion of condom usage, and 
need to follow healthy hygienic practices is the most cost effective approach in reducing the incidence 
of cervical carcinoma in resource-crunched societies.
CONCLUSION 
The study generates data of prevalence of sub-clinical HPV in women visiting a tertiary care 
institution. 
1. Prevalence of HPV 16 in symptomatic women attending our OPD is 64% which is high.
2.  HPV 16 prevalence is more in women who start their sexual activity at a younger age
3.  HPV 16 prevalence is high in women belonging to the lower socioeconomic strata.
4. HPV 16 prevalence is more in illiterate population.
Identification of population at risk will enable focussed screening, with a greater cost effective 
utilization of resources. The data generated will be useful for laying guidelines for mass screening of 
HPV, treatment and prophylaxis in the local population and vaccination against HPV.
The implications of the study are that women belonging to the lower socioeconomic strata must be 
counselled regarding the following
1. Need for frequent follow-up to identify cancer cervix in early stages
2. Patients with persistent HPV positivity and those who have completed their family can 
be given the option of hysterectomy to avoid the progression to cancer cervix.
3. Emphasis on vaccination against HPV 
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